Literature DB >> 3977213

Prognosis in Behcet's disease.

P Pivetti Pezzi, V Gasparri, P De Liso, G Catarinelli.   

Abstract

A retrospective clinical study made to determine the course and prognosis of the disease in 51 cases of Behçet's disease, with a follow-up of at least one year (average five years, range 1 to 15 years), showed that 45% of the eyes kept visual acuities of 1/10 or less, and 44% 8/10 or better, four years after the onset of the ocular symptoms. Ten years later, some 50% of the eyes had visual acuities of 1/10 or less and 32% had acuities of 8/10 or better. In the group of patients who were treated early with chlorambucil, the eye prognosis was significantly improved.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3977213

Source DB:  PubMed          Journal:  Ann Ophthalmol        ISSN: 0003-4886


  10 in total

1.  Efficacy and safety of biological therapy compared to synthetic immunomodulatory drugs or placebo in the treatment of Behçet's disease associated uveitis: a systematic review.

Authors:  Ana Urruticoechea-Arana; Tatiana Cobo-Ibáñez; Virginia Villaverde-García; Montserrat Santos Gómez; Estíbaliz Loza; Kelly Vargas-Osorio; Leslie Fariñas Padrón; Federico Diaz-Gonzalez; Vanesa Calvo-Río; Ricardo Blanco
Journal:  Rheumatol Int       Date:  2018-11-12       Impact factor: 2.631

Review 2.  Outcome measures used in clinical trials for Behçet syndrome: a systematic review.

Authors:  Gulen Hatemi; Peter A Merkel; Vedat Hamuryudan; Maarten Boers; Haner Direskeneli; Sibel Z Aydin; Hasan Yazici
Journal:  J Rheumatol       Date:  2014-02-01       Impact factor: 4.666

3.  Retinal and disc neovascularization in Behçet's disease and efficacy of laser photocoagulation.

Authors:  L S Atmaca; F Batioğlu; A Idil
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-02       Impact factor: 3.117

4.  Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement.

Authors:  Masaru Takeuchi; Hideyuki Hokama; Rintaroh Tsukahara; Takeshi Kezuka; Hiroshi Goto; Jun-Ichi Sakai; Masahiko Usui
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-06-28       Impact factor: 3.117

5.  [Ocular involvement in Behçet's disease: first 5-year-results for visual development after treatment with interferon alfa-2a].

Authors:  C M E Deuter; I Kötter; I Günaydin; M Zierhut; N Stübiger
Journal:  Ophthalmologe       Date:  2004-02       Impact factor: 1.059

6.  Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.

Authors:  Massimo Accorinti; Maria Pia Pirraglia; Maria Pia Paroli; Roberta Priori; Fabrizio Conti; Paola Pivetti-Pezzi
Journal:  Jpn J Ophthalmol       Date:  2007-06-07       Impact factor: 2.447

7.  Urticaria/arthritis syndrome: report of four B51 positive patients.

Authors:  G Pasero; I Olivieri; G Gemignani; C Vitali
Journal:  Ann Rheum Dis       Date:  1989-06       Impact factor: 19.103

Review 8.  Decision-making and management of uveitic cataract.

Authors:  Nicole Shu-Wen Chan; Seng-Ei Ti; Soon-Phaik Chee
Journal:  Indian J Ophthalmol       Date:  2017-12       Impact factor: 1.848

9.  Cataract surgery under systemic infliximab therapy in patients with refractory uveitis associated with Behcet disease.

Authors:  Abdullah Alfawaz; Sultan Alrashidi; Hatem Kalantan; Hani Al-Mezaine; Ahmed M Abu
Journal:  Ann Saudi Med       Date:  2014 Jul-Aug       Impact factor: 1.526

10.  Relationship between the higher inflammatory cytokines level in the aqueous humor of Fuchs uveitis syndrome and the presence of cataract.

Authors:  Hui Wang; Yong Tao
Journal:  BMC Ophthalmol       Date:  2021-02-27       Impact factor: 2.209

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.